ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Outcomes Following Renal Transplant with Hepatitis C Viremic Donors in an Elderly Veteran Population with Preemptive Mayvret Therapy

R. Lopez-Soler1, A. Thorndyke1, C. Trotter1, A. Abadier2, M. Samra1

1Surgery, Transplantation, Edward Hines Jr. Veterans Administration Hospital, Hines, IL, 2Surgery, Loyola University School of Medicine, Maywood, IL

Meeting: 2022 American Transplant Congress

Abstract number: 727

Keywords: Donors, marginal, Elderly patients, Hepatitis C, Kidney transplantation

Topic: Clinical Science » Kidney » 32 - Kidney Deceased Donor Selection

Session Information

Session Name: Kidney Deceased Donor Selection

Session Type: Poster Abstract

Date: Saturday, June 4, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 5:30pm-7:00pm

Location: Hynes Halls C & D

*Purpose: Overall mortality on the kidney transplant waiting list is higher for older diabetic patients. The average age of waitlisted veteran patients is 64, with patients listed up through the age of 75. Expansion of the donor pool would result in increased transplantation rates and decrease mortality on the waitlist. Recent data has shown the safety and benefits of using kidneys from HCV viremic [HCV NAT (+)] donors. However, these studies were limited to younger patients with initiation of therapy post-transplant. This study aims to determine the safety and efficacy of a pre-emptive treatment protocol in an elderly veteran population.

*Methods: This is a prospective, open-label trial. Our cohorts were: 15 deceased donor kidney transplant (DDKT) recipients with HCV NAT (+) kidneys and 20 DDKT recipients with negative HCV NAT testing donors transplanted between 11/2020 and 11/2021. HCV NAT (+) recipients were treated with once-daily Mayvret (Glecaprevir 300mg/Pibrentasvir 120mg) started at least 30 minutes pre-operatively and continued for 8 weeks. Sustained virologic response 12 weeks (SVR 12) was determined by negative NAT testing. Other endpoints included liver function, adverse effects, and patient and graft survival.

*Results: HCV NAT (+) donors were younger (61.3 vs 64.7 yrs., p=0.011). Donor Age, KDPI, and cold ischemia time (CIT) were equivalent amongst both cohorts [HCV NAT (+), 38.85 yrs. vs 41.3 yrs., 59.5% vs 57.56%, and 21.6 hrs. vs. 18.1 hrs.; p>0.05]. Qualifying listing days and dialysis vintage was not-significantly different amongst both cohorts. 40% of HCV NAT (+) recipients had detectable HCV viral load on post-operative day (POD) 1, though all patients achieved undetectable HCV viral load by POD7. SVR12 is 100% in 11/15 patients, with the remaining four patients currently negative. There was no BPAR and 100% Patient and Graft Survival. One patient developed BK viremia. 13% developed persistently elevated bilirubin levels (>1 mg/dl) 1-month post-transplant. One patient developed >1gram of proteinuria after achieving SVR12. However, median serum creatinine was better in the HCV NAT (+) Cohort [1.23 (0.6-2.03) mg/dL vs 1.82 (1-2.62) mg/dL, p-value 0.014].

*Conclusions: Low to no copays allowed for preemptive antiviral initiation in the veteran population. Additionally, differences in KDPI are not truly reflective of actual donor risk as HCV increases KDPI calculation. However, HCV NAT (+) transplants with a pre-emptive treatment protocol results in improved graft function with minimal to no complications in an elderly veteran population. Long-term outcomes will allow for increasing use of HCV NAT (+) donors for all patient populations.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Lopez-Soler R, Thorndyke A, Trotter C, Abadier A, Samra M. Outcomes Following Renal Transplant with Hepatitis C Viremic Donors in an Elderly Veteran Population with Preemptive Mayvret Therapy [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-following-renal-transplant-with-hepatitis-c-viremic-donors-in-an-elderly-veteran-population-with-preemptive-mayvret-therapy/. Accessed June 17, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences